Bausch Health Companies (BHC) Other Non-Current Assets (2009 - 2026)
Bausch Health Companies (BHC) posted Other Non-Current Assets of $358.0 million for Q2 2026, down 2.98% sequentially from $369.0 million in Q1 2026, and down 7.73% YoY from $388.0 million in Q2 2025.
Bausch Health Companies (BHC) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Bausch Health Companies has reported Other Non-Current Assets for 18 years, with the latest figure at $358.0 million in Q2 2026.
- Quarterly Other Non-Current Assets fell 7.73% year-over-year to $358.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $358.0 million (down 7.73% YoY) and the FY2025 annual result came in at $378.0 million, up 4.13% from the prior year.
- Other Non-Current Assets fell to $358.0 million in Q2 2026 per BHC's latest filing, from $369.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $389.0 million in Q3 2024 and troughed at $307.0 million in Q4 2023.
- A 5-year average of $348.1 million and a median of $339.5 million in 2022 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets tumbled 45.87% in 2022, then grew 21.79% in 2025.
- Over 5 years, Other Non-Current Assets stood at $326.0 million in 2022, then decreased by 5.83% to $307.0 million in 2023, then increased by 18.24% to $363.0 million in 2024, then rose by 4.13% to $378.0 million in 2025, then slipped by 5.29% to $358.0 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $358.0 million, $369.0 million, and $378.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | Bausch Health Companies | 2.42 Bn | 586.38 Mn | 2.10 Bn | 358.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 358.00 Mn |
| Mar 31, 2026 | 369.00 Mn |
| Dec 31, 2025 | 378.00 Mn |
| Sep 30, 2025 | 382.00 Mn |
| Jun 30, 2025 | 388.00 Mn |
| Mar 31, 2025 | 380.00 Mn |
| Dec 31, 2024 | 363.00 Mn |
| Sep 30, 2024 | 389.00 Mn |
| Jun 30, 2024 | 329.00 Mn |
| Mar 31, 2024 | 312.00 Mn |
| Dec 31, 2023 | 307.00 Mn |
| Sep 30, 2023 | 328.00 Mn |
| Jun 30, 2023 | 325.00 Mn |
| Mar 31, 2023 | 318.00 Mn |
| Dec 31, 2022 | 326.00 Mn |
| Sep 30, 2022 | 341.00 Mn |
| Jun 30, 2022 | 338.00 Mn |
| Mar 31, 2022 | 334.00 Mn |
| Dec 31, 2021 | 340.00 Mn |
| Sep 30, 2021 | 343.00 Mn |